Following presentation of the PRINCE at ASCO 2016, should we be offering intermittent docetaxel to patients with metastatic castration-resistant prostate cancer?

The simple answer is no, as this study was dramatically underpowered to reach any conclusion. A couple of issues:

1. This trial was designed after the TAX 327 data showed q3 week therapy to be the standard of care. This trial allowed weekly therapy anyway, likely because some of their docs wanted to ...